Graybug Vision

Graybug Vision

Graybug Vision was founded in 2010 by David Guyer and Anthony Adamis, two ophthalmology researchers whose earlier work had helped establish anti-VEGF therapy as the standard of care for retinal disease. Guyer and Adamis had previously co-founded Eyetech Pharmaceuticals, which developed Macugen, the first anti-VEGF drug approved for wet AMD. Graybug was built around a proprietary microparticle technology designed to deliver drugs over six months or longer from a single injection. The company's core development program, GB-102, is a sustained-release formulation of sunitinib targeting VEGF and PDGF pathways. Graybug's strategy involves both internal pipeline assets and partnerships with larger pharmaceutical firms. It has conducted Phase 2 clinical trials for wet AMD and diabetic macular edema, with data reported per clinical trial registries and SEC filings. Graybug raised $137M in its SPAC merger in 2021, valuing the company at approximately $680M at listing (per SEC filings, 2021). Total venture funding before the SPAC included rounds from firms such as Blackstone Life Sciences and The Baupost Group. The company maintains a small corporate team in Redwood City, California, with no disclosed separate family office structure. Graybug's structural differentiator lies in its microparticle drug delivery platform, which aims to shift retinal disease treatment from monthly clinic visits to biannual injections. The company's governance includes a scientific advisory board drawn from leading academic medical centers, and its management team has deep drug-development experience from prior ophthalmic successes.